Cefpiramide
Appearance
(Redirected from C25H24N8O7S2)
This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. (November 2024) |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intravenous, intramuscular |
ATC code | |
Pharmacokinetic data | |
Protein binding | 93% to 99.3% |
Elimination half-life | 4.44 hours |
Excretion | Renal and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H24N8O7S2 |
Molar mass | 612.64 g·mol−1 |
3D model (JSmol) | |
Melting point | 213 to 215 °C (415 to 419 °F) (dec.) |
| |
| |
(what is this?) (verify) |
Cefpiramide is a third-generation cephalosporin antibiotic.[citation needed]
References
[edit]External links
[edit]- Wang H, Yu Y, Xie X, Wang C, Zhang Y, Yuan Y, Zhang X, Liu J, Wang P, Chen M (2000). "In-vitro antibacterial activities of cefpiramide and other broad-spectrum antibiotics against 440 clinical isolates in China". J Infect Chemother. 6 (2): 81–85. doi:10.1007/PL00012156. PMID 11810540. S2CID 30532462.
- Iakovlev V, Vishnevskiĭ V, Khlebnikov E, Khadin I, Plavlova M, Elagina L, Izotova G (1995). "[Cefpiramide (Tamicin) in the treatment of purulent complications of abdominal surgery]". Antibiot Khimioter. 40 (9): 30–4. PMID 8651827.
- Sampi K, Hattori M (1992). "[Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study]". Gan to Kagaku Ryoho. 19 (9): 1315–20. PMID 1503486.